Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2011-09-13 18:38:52
Reporting Period:
Filing Date:
Accepted Time:
2011-09-13 18:38:52
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1178711 Transcept Pharmaceuticals Inc TSPT Pharmaceutical Preparations (2834) 330960223
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1428158 J Frederick Ruegsegger C/o Transcept Pharmaceuticals, Inc.
1003 W. Cutting Blvd, Suite 110
Point Richmond CA 94804
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-09-13 15,000 $2.86 15,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
  1. The purchase price reported in column 4 of Table 1 represents the weighted average purchase price of the shares purchased ranging from $2.83 to $2.89 per share. Upon request of the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price.